CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 112 enrolled
Drug / intervention
Yohimbine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00535002
NCT00535002Phase 2Completed
CompareCT.gov

SCOR on Sex and Gender Factors Affecting Women's Health

Medical University of South Carolina·interventional·Posted Sep 26, 2007·Updated Jun 7, 2017

In Brief

A Phase 2 clinical trial evaluating Yohimbine and Placebo for Cocaine Related Disorders. Completed, enrolled 112 participants across 1 site.

Detailed Summary

Stress and cues reminiscent of cocaine use promote craving and relapse in cocaine dependent individuals. In addition, there appears to be gender differences in determinants of relapse to drug use following abstinence in cocaine-dependent individuals. Therefore the purpose of the present study is to study the role of hormonal status on the response to cocaine-related cues with or without stress in cocaine-dependent women and men.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCocaine Related Disorders
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA), Office of Research on Women's Health (ORWH)

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 26, 2007
Enrollment StartSep 1, 2007
Primary CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 18.8 years ago

Interventions

Yohimbinedrug

Participants were pre-treated with either yohimbine or placebo.

Placebodrug